Drug Trial Radar · NCT01109693
Strategic Use of New Generation Antidepressants for Depression
Last checked: Nov 20, 2026Latest source record: Oct 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,011
Actual
Start
Dec 2010
Primary completion
Sep 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Kyoto UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center of Neurology and Psychiatry, Japan
- First posted
- Apr 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.
Conditions
- Unipolar Major Depressive Episode
Interventions
SertralineDrug
Sertraline 50 mg/d or 100 mg/d for 6 more weeks
MirtazapineDrug
Augment with or switch to mirtazapine 15-45 mg/d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observer-rated depression severity (PHQ-9)Time frame: 9 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Kochi Medical School Hospital
Nangoku, Kochi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.